GlassScriptPhysician profile
Rani Whitfield
NPI 1497768147
$4,899.76
in general payments reported to CMS, 2019-2025
28 companies · $440 in 2025
The $440 reported for 2025 was more than what 81% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $1,023 · 2021: $966 · 2022: $284 · 2023: $635 · 2024: $873 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $780.75 | 2023-2025 | Xeomin |
| Lilly USA, LLC | $597.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $521.99 | 2019-2022 | |
| Novo Nordisk INC | $517.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $388.16 | 2019-2023 | Lagevrio, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.30 | 2019-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $355.49 | 2019-2024 | Breztri, Airsupra, Fasenra |
| Abbott Laboratories | $234.34 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $180.14 | 2019-2024 | |
| Abbvie INC. | $142.53 | 2023-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $111.76 | 2019-2023 | |
| Amgen INC. | $101.94 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $96.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $86.85 | 2020-2024 | Shingrix, Arexvy |
| Allergan, INC. | $72.58 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.11 | 2024-2025 | Dexcom G6 Transmitter |
| Clarus Therapeutics INC. | $42.55 | 2021 | |
| Viiv Healthcare Company | $33.81 | 2023-2024 | Apretude |
| Arbor Pharmaceuticals, INC. | $30.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.92 | 2021 | |
| Sanofi Pasteur INC. | $27.86 | 2019-2025 | |
| Antares Pharma, INC. | $26.55 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.18 | 2021 | |
| Dynavax Technologies Corporation | $21.50 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2021 | |
| Cequr Corporation | $16.88 | 2025 | Cequr Simplicity |
| Acerus Pharmaceuticals Corporation | $16.65 | 2021 | |
| Adlon Therapeutics L.P. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.